Protein kinase C signaling and cell cycle regulation
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
A link between T cell proliferation and the protein kinase C (PKC) family of serine/threonine kinases has been recognized for about 30 years. However, despite the wealth of information on PKC-mediated control of, T cell activation, understanding of the effects of PKCs on the cell cycle machinery in this cell type remains limited. Studies in other systems have revealed important cell cycle-specific effects of PKC signaling that can either positively or negatively impact proliferation. The outcome of PKC activation is highly context-dependent, with the precise cell cycle target(s) and overall effects determined by the specific isozyme involved, the timing of PKC activation, the cell type, and the signaling environment. Although PKCs can regulate all stages of the cell cycle, they appear to predominantly affect G0/G1 and G2. PKCs can modulate multiple cell cycle regulatory molecules, including cyclins, cyclin-dependent kinases (cdks), cdk inhibitors and cdc25 phosphatases; however, evidence points to Cip/Kip cdk inhibitors and D-type cyclins as key mediators of PKC-regulated cell cycle-specific effects. Several PKC isozymes can target Cip/Kip proteins to control G0/G1 → S and/or G2 → M transit, while effects on D-type cyclins regulate entry into and progression through G1. Analysis of PKC signaling in T cells has largely focused on its roles in T cell activation; thus, observed cell cycle effects are mainly positive. A prominent role is emerging for PKCθ, with non-redundant functions of other isozymes also described. Additional evidence points to PKCδ as a negative regulator of the cell cycle in these cells. As in other cell types, context-dependent effects of individual isozymes have been noted in T cells, and Cip/Kip cdk inhibitors and D-type cyclins appear to be major PKC targets. Future studies are anticipated to take advantage of the similarities between these various systems to enhance understanding of PKC-mediated cell cycle regulation in T cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
Castagna, M., Takai, Y., Kaibuchi, K., Sano, K., Kikkawa, U., & Nishizuka, Y. (1982) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)34459-4 · Cited by 4,725 · cited 3×
“Shortly thereafter, it was determined that PKC, then recognized as a calcium-dependent enzyme, represented the major cellular receptor for phorbol esters (Castagna et al., 1982) and it was not long before the connection between these phenomena was made (Isakov et al.”
BackgroundSmith-Garvin, J. E., Koretzky, G. A., & Jordan, M. S. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132706 · Cited by 2,144
Cyclin D as a therapeutic target in cancer
Musgrove, E. A., Caldon, C. E., Barraclough, J., Stone, A., & Sutherland, R. L. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3090 · Cited by 1,370 · cited 1×
“Entry of quiescent cells into the cell cycle and transit through early G1 is regulated by D-type cyclins, which complex with cdk4 and cdk6 (Musgrove et al., 2011).”
BackgroundSibling rivalry in the E2F family
Trimarchi, J. M., & Lees, J. A. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm714 · Cited by 1,158 · cited 2×
“In contrast, the atypical PKCs (PKCζ and PKCι/λ) are not dependent on lipid second messengers or calcium for activity.”
BackgroundLiving with or without cyclins and cyclin-dependent kinases
Sherr, C. J., & Roberts, J. M. (2004) · Genes & Development · doi:10.1101/gad.1256504 · Cited by 1,089 · cited 2×
“Several excellent reviews have been written on the regulation of the cell cycle (Sherr and Roberts, 2004; Cobrinik, 2005; Malumbres and Barbacid, 2005; Du and Pogoriler, 2006; Satyanarayana and Kaldis, 2009) and only a brief description will be given here.”
BackgroundMethodProtein kinase C and other diacylglycerol effectors in cancer
Griner, E. M., & Kazanietz, M. G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2110 · Cited by 978
Protein kinase C as a possible receptor protein of tumor‐promoting phorbol esters
Kikkawa, U., Takai, Y., Tanaka, Y., Miyake, R., & Nishizuka, Y. (1983) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)44245-1 · Cited by 881 · cited 1×
“The fact that PKCs are activated by tumor promoting phorbol esters and are downstream of growth factor receptors initially led to the idea that they transduce positive mitogenic signals (Castagna et al., 1982; Kikkawa et al., 1983; Leach et al., 1983).”
BackgroundRegulation of Immune Responses by mTOR
Powell, J. D., Pollizzi, K. N., Heikamp, E. B., & Horton, M. R. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-075024 · Cited by 836 · cited 1×
“Given the emerging importance of mTOR in immune function (Powell et al., 2012), an area of particular interest is the interplay between PKC and mTOR signaling in control of T cell proliferation under the metabolic conditions in which activation occurs in vivo.”
BackgroundSutherland, R., Delia, D., Schneider, C., Newman, R., Kemshead, J., & Greaves, M. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.7.4515 · Cited by 685 · cited 1×
“Over 30 years ago, it was determined that a combination of phorbol esters and elevated intracellular calcium potently induces proliferation of cells of the T cell lineage (e.g., Whitfield et al., 1973; Lyall et al., 1980; Sutherland et al., 1981).”
Background
Cited by
Tumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
Equivocal, explicit and emergent actions of PKC isoforms in cancer
Parker, P. J., Brown, S. J., Calleja, V., Chakravarty, P., Cobbaut, M., Linch, M., Marshall, J. J. T., Martini, S., McDonald, N. Q., Soliman, T., et al. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00310-4 · Cited by 65
Ceftriaxone Protects Astrocytes from MPP+ via Suppression of NF-ΚB/JNK/c-Jun Signaling
Zhang, Y., Zhang, X., & Qu, S. (2015) · Molecular Neurobiology · doi:10.1007/s12035-014-8845-z · Cited by 39
“PKCαwas suggested to affect the G1 phase to the S phase transit via downregulation of cyclinD1 [46], and the trend in the expression of PKCαwas similar to that of CDK4 and cyclinD1 (Fig.”
D’Incal, C., Broos, J., Torfs, T., Kooy, R. F., & Vanden Berghe, W. (2022) · Cells · doi:10.3390/cells11081325 · Cited by 29
Smiljanić, K., Prodić, I., Trifunovic, S., Krstić Ristivojević, M., Aćimović, M., Stanković Jeremić, J., Lončar, B., & Tešević, V. (2023) · Antioxidants · doi:10.3390/antiox12111988 · Cited by 24
“…signalling could cause a slowdown of the cell cycle by inhibiting adenylyl cyclase, reducing the cell cAMP and consequently reducing protein kinase C activity, which in turn will lead to a decreased level of T cell proliferation [85] or decreased vascular smooth muscle cell proliferation [73].”
Background
Metadata
- Authors
- Black, A. R., & Black, J. D.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2013
- Volume
- 3
- Pages
- 423-423
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2146964357
- Cited by
- 125
- References
- 15
- FWCI
- 3.09
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.